|
|
|
Bold. That’s how we at The Leukemia & Lymphoma Society
(LLS) would describe our journey last year. It’s a journey we
couldn’t have made without your support.
In 2022, LLS took bold steps to improve the futures of blood
cancer patients and survivors dealing with more than 100 blood
cancers, including leukemia, lymphoma, and myeloma.
|
|
Here
are just a few highlights:
- 14
new blood cancer treatment options were
approved by the FDA, many because of longstanding LLS
support.
- We
funded 117 scientists and invested in 17 Therapy
Acceleration Program (TAP) partners to
advance next-generation blood cancer research worldwide.
- The
Dare to Dream Project was launched to transform treatment and
care for kids with blood cancer, along with our PedAL Master Clinical Trial
to expedite safer, more targeted, more effective treatments
for pediatric acute leukemia.
- We increased financial assistance for
patients and families by 60%, providing over $385
million in awards to more than 75,000 patients.
- We
expanded education and support services for
patients, survivors, families, and healthcare
professionals.
- We
advanced health equity efforts by
funding research to uncover the root causes of healthcare
disparities, expanding Latino and Black community outreach,
and improving access and diversity in clinical trials.
- We
led federal and local advocacy efforts to
victories, such as helping to pass a Medicare law to limit patients’
prescription drug costs, and leading efforts to
end “junk” insurance.
And that’s just part of our story! Check out our 2022 Annual Report to see the
full scope of what your astonishing support has helped us
accomplish—and what’s on our horizon.
|
|
|
|
|
|
|
|
|
|
|
No comments:
Post a Comment